Alberto Broniscer Selected Research

Erlotinib Hydrochloride (CP 358,774)

2/2020	Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
10/2019	Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
9/2018	Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.
1/2014	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas.
4/2012	Brain tumor therapy-induced changes in normal-appearing brainstem measured with longitudinal diffusion tensor imaging.
7/2009	Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
1/2009	Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
3/2007	Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Broniscer Research Topics

Disease

41	Neoplasms (Cancer) 01/2022 - 01/2004
36	Glioma (Gliomas) 07/2022 - 01/2004
25	Diffuse Intrinsic Pontine Glioma 01/2022 - 11/2010
24	Brain Neoplasms (Brain Tumor) 01/2022 - 07/2007
9	Medulloblastoma 01/2021 - 10/2006
5	Glioblastoma (Glioblastoma Multiforme) 08/2017 - 01/2004
4	Exanthema (Rash) 01/2020 - 06/2008
4	Diarrhea 10/2019 - 07/2007
4	Hearing Loss (Hearing Impairment) 04/2015 - 04/2014
4	Central Nervous System Neoplasms 03/2015 - 07/2007
3	Neuroepithelial Neoplasms (Gliomatosis Cerebri) 10/2022 - 02/2006
3	Primitive Neuroectodermal Tumors (PNET) 10/2022 - 03/2004
3	Hemorrhage 01/2020 - 12/2010
3	Disease Progression 01/2016 - 01/2005
3	Ototoxicity 03/2015 - 08/2008
3	Rhabdoid Tumor (Rhabdoid Tumors) 04/2012 - 03/2005
3	Astrocytoma (Pilocytic Astrocytoma) 06/2009 - 02/2007
2	Brain Stem Neoplasms (Brain Stem Tumor) 01/2020 - 04/2008
2	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2010
2	Neutropenia 06/2008 - 01/2005
2	Infections 06/2008 - 03/2007
1	Typical Teratoid Rhabdoid Tumor 01/2023
1	Sarcoma (Soft Tissue Sarcoma) 10/2022
1	Neuroblastoma 10/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Craniopharyngioma (Craniopharyngiomas) 11/2020
1	Neurologic Manifestations (Neurological Manifestations) 03/2020
1	Nervous System Diseases (Neurological Disorders) 01/2020
1	Cytopenia 02/2018
1	Vomiting 02/2018
1	Genetic Predisposition to Disease (Genetic Predisposition) 12/2017
1	Abscess 05/2015
1	2-Hydroxyglutaricaciduria 03/2015
1	Primary Ovarian Insufficiency 01/2015
1	Deafness (Deaf Mutism) 06/2014

Drug/Important Bio-Agent (IBA)

26	dipinacoline glutamateIBA 01/2022 - 12/2010
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2020 - 03/2007
6	Cisplatin (Platino)FDA LinkGeneric 04/2015 - 08/2008
5	Histones (Histone)IBA 01/2022 - 01/2012
5	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 01/2005
4	Phosphotransferases (Kinase)IBA 01/2021 - 01/2009
4	ErbB Receptors (EGF Receptor)IBA 10/2019 - 11/2010
4	vandetanib (ZD6474)IBA 09/2013 - 11/2010
3	Methionine (L-Methionine)FDA Link 07/2022 - 01/2022
3	EnzymesIBA 01/2022 - 01/2009
3	OSI-420IBA 02/2020 - 01/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 10/2010
3	Dasatinib (BMS 354825)FDA Link 01/2018 - 06/2013
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 09/2013 - 11/2010
3	Farnesyltranstransferase (Farnesyltransferase)IBA 03/2011 - 07/2007
2	RNA (Ribonucleic Acid)IBA 01/2020 - 10/2010
2	dabrafenibIBA 12/2019 - 12/2019
2	CrizotinibIBA 01/2018 - 06/2014
2	Alkylating AgentsIBA 01/2015 - 03/2005
2	Amifostine (Ethyol)FDA LinkGeneric 06/2014 - 08/2008
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2014 - 11/2010
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2012 - 08/2008
2	Vincristine (Oncovin)FDA LinkGeneric 08/2012 - 08/2008
2	tipifarnib (R115777)IBA 03/2011 - 06/2008
2	Gefitinib (Iressa)FDA Link 03/2011 - 12/2010
1	MLN 8237IBA 01/2023
1	Lysine (L-Lysine)FDA Link 01/2022
1	Amino Acids FDA Link 01/2022
1	Small Interfering RNA (siRNA)IBA 01/2022
1	Methionine AdenosyltransferaseIBA 01/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	tyrosyltyrosine (Tyr-Tyr)IBA 01/2021
1	crenolanibIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	LigandsIBA 01/2021
1	InterferonsIBA 11/2020
1	veliparibIBA 01/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2019
1	Alanine Transaminase (SGPT)IBA 02/2018
1	Capecitabine (Xeloda)FDA Link 02/2018
1	TabletsIBA 02/2018
1	Monophenol Monooxygenase (Tyrosinase)IBA 01/2018
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2016
1	posaconazole FDA Link 05/2015
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 05/2015
1	Micafungin (FK463)FDA Link 05/2015
1	alpha-hydroxyglutarateIBA 03/2015
1	Methotrexate (Mexate)FDA LinkGeneric 01/2015

Therapy/Procedure

36	Radiotherapy 01/2021 - 01/2004
23	Therapeutics 10/2022 - 01/2004
15	Drug Therapy (Chemotherapy) 10/2022 - 01/2004
7	Craniospinal Irradiation 09/2015 - 03/2008
3	Aftercare (After-Treatment) 09/2015 - 08/2008
3	Hearing Aids (Hearing Aid) 06/2014 - 08/2008
2	Conformal Radiotherapy 03/2020 - 12/2014
1	Immunotherapy 01/2021
1	Re-Irradiation 01/2020
1	Retreatment 01/2020
1	Duration of Therapy 12/2019
1	Biological Therapy 01/2018
1	Cytoreduction Surgical Procedures 01/2016
1	Ambulatory Care (Outpatient Care) 01/2016
1	Palliative Care (Palliative Therapy) 01/2016
1	Combined Modality Therapy 01/2016
1	Adjuvant Chemotherapy 01/2015